2021 · New England Journal of Medicine
Dexamethasone in Hospitalized Patients with Covid-19
Verdict
UNSCIENTIFIC
The study follows the scientific method inside its paradigm. The paradigm itself does not pass. The worse layer decides. The verdict is unscientific.
1·Study methodology · inside the paradigm
SCIENTIFIC
Follows the scientific method within Allopathic Medicine.
2·Paradigm · Allopathic Medicine
UNSCIENTIFIC
Fails the tests. The worse layer decides.
How the verdict is decided
The verdict grades both layers: the paradigm this study assumes, and how the study was carried out inside it. Both must be scientific for the whole thing to be scientific. A clean method inside an unscientific paradigm is unscientific. An unscientific method inside a better paradigm is unscientific. A split on either layer is mixed. The worse layer decides.
1·Study methodology
Did this study test its claim with methods that are independent, falsifiable, and non-circular?
SCIENTIFIC
The study claims that dexamethasone reduces 28-day death in hospitalized patients diagnosed with COVID-19. All three tests pass.
Independently Verifiable
Pass
A stranger who rejects the entire framework can still count whether a person died within 28 days of being assigned to a group.
Falsifiable
Pass
If the death count in the dexamethasone group had been equal to or higher than the usual care group, the claim that dexamethasone reduces mortality would have been falsified.
Non-Circular
Pass
The instrument measuring the claim is arithmetic on a public outcome, not a probe built from a prior model.
Why
Doctors put 6 mg of dexamethasone into 2104 hospitalized patients once a day for up to ten days, and left 4321 others on usual care. Then they counted who was dead 28 days later. 482 in the drug group, 1110 in the other. The count was the whole measurement. No probe, no curve, no interpretation sitting between the event and the number. If the drug group had died at the same rate or faster, the claim would have been falsified, and the arithmetic was free to come out that way. That is why the study passes. The patients were sorted into the trial by a diagnosis that assumes the allopathic model, but that sits on Layer 2. The survival difference itself was measured by counting bodies.
2·Paradigm · Allopathic Medicine
Does the framework this study assumes pass the three tests?
UNSCIENTIFIC
Independently Verifiable
Fail
Every patient in the trial was sorted into the cohort by a diagnosis that required accepting the allopathic model first. The population itself is a model-dependent artifact.
Falsifiable
Fail
If dexamethasone had failed, nobody would have concluded that the allopathic model is wrong; they would have concluded this drug was suboptimal for this condition.
Non-Circular
Fail
The disease category was defined by tests built to find what the model already named, the drug targets a mechanism the model invented, and the survival difference is then cited as proof the model works.
Why
The allopathic model treats symptoms as the disease rather than as the body's response to underlying damage. Dexamethasone suppresses inflammation, which the model calls the disease. The trial proves that suppressing inflammation keeps more people alive for 28 days. It does not prove the model understands why those people were sick, why their lungs were damaged, or what conditions produced the damage in the first place. The patient cohort was defined by what they diagnosed as clinically suspected or laboratory-confirmed SARS-CoV-2 infection, a category produced by model-dependent tests. The drug targets a mechanism the model named. The outcome is counted as a win for the model. If the drug had failed, the model would have absorbed the failure as a dosing problem or a wrong drug, never as evidence the framework itself is wrong. That is an unfalsifiable loop. The study methodology is sound. The framework that generated it is not.
From the study
Eligible patients were those who were hospitalized with clinically suspected or laboratory-confirmed SARS-CoV-2 infection.
The primary outcome was 28-day mortality.
Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization.